Monument Capital Management Sells 33 Shares of Stryker Corporation $SYK

Monument Capital Management lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 5.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 609 shares of the medical technology company’s stock after selling 33 shares during the period. Monument Capital Management’s holdings in Stryker were worth $241,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of SYK. Brighton Jones LLC lifted its stake in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after acquiring an additional 609 shares in the last quarter. GAMMA Investing LLC lifted its stake in Stryker by 16.4% in the 1st quarter. GAMMA Investing LLC now owns 5,574 shares of the medical technology company’s stock valued at $2,075,000 after acquiring an additional 785 shares in the last quarter. Integrated Advisors Network LLC lifted its stake in Stryker by 10.7% in the 1st quarter. Integrated Advisors Network LLC now owns 3,781 shares of the medical technology company’s stock valued at $1,407,000 after acquiring an additional 366 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Stryker by 1.1% in the 1st quarter. Assenagon Asset Management S.A. now owns 10,375 shares of the medical technology company’s stock valued at $3,862,000 after acquiring an additional 110 shares in the last quarter. Finally, Focus Financial Network Inc. bought a new stake in Stryker in the 1st quarter valued at approximately $214,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on SYK. Weiss Ratings restated a “buy (b-)” rating on shares of Stryker in a research note on Wednesday. Evercore ISI cut their target price on Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a research note on Tuesday. Wells Fargo & Company boosted their price target on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Rothschild & Co Redburn assumed coverage on Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price target on the stock. Finally, Truist Financial set a $415.00 price target on Stryker and gave the stock a “hold” rating in a research report on Monday, August 4th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $430.10.

Insider Buying and Selling

In related news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Stock Down 1.5%

SYK stock opened at $364.77 on Friday. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm has a market capitalization of $139.46 billion, a PE ratio of 48.31, a PEG ratio of 2.67 and a beta of 0.94. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The business’s 50 day simple moving average is $380.25 and its 200 day simple moving average is $378.75.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.9%. Stryker’s payout ratio is presently 44.50%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.